Skye Bioscience, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Skye Bioscience is a clinical-stage biopharmaceutical company developing therapies that target the endocannabinoid system, with its lead candidate nimacimab, an antibody targeting the CB1 receptor, being studied for obesity and related metabolic conditions.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Schwab Andrew J.Insider | Sell | $62K | 32,607at $1.91 | Sep 16, 2026 |
| 5AM Partners VII, LLCInsider | Sell | $62K | 32,607at $1.91 | Sep 16, 2026 |
| Schwab Andrew J.Insider | Sell | $2K | 1,285at $1.91 | Sep 16, 2026 |
| 5AM Partners VII, LLCInsider | Sell | $2K | 1,285at $1.91 | Sep 16, 2026 |
| Schwab Andrew J.Insider | Sell | $17K | 45,090at $0.38 | Aug 18, 2026 |
| 5AM Partners VII, LLCInsider | Sell | $17K | 45,090at $0.38 | Aug 18, 2026 |
| Schwab Andrew J.Insider | Sell | $4K | 10,255at $0.35 | Aug 19, 2026 |
| 5AM Partners VII, LLCInsider | Sell | $4K | 10,255at $0.35 | Aug 19, 2026 |
| Schwab Andrew J.Insider | Sell | $2K | 6,495at $0.32 | Aug 20, 2026 |
| 5AM Partners VII, LLCInsider | Sell | $2K | 6,495at $0.32 | Aug 20, 2026 |
| Schwab Andrew J.Insider | Sell | $695 | 1,830at $0.38 | Aug 18, 2026 |
| Schwab Andrew J.Insider | Sell | $96K | 253,080at $0.38 | Aug 18, 2026 |
| Schwab Andrew J.Insider | Sell | $371 | 1,159at $0.32 | Aug 20, 2026 |
| 5AM Partners VII, LLCInsider | Sell | $371 | 1,159at $0.32 | Aug 20, 2026 |
| Schwab Andrew J.Insider | Sell | $143 | 409at $0.35 | Aug 19, 2026 |
| 5AM Partners VII, LLCInsider | Sell | $143 | 409at $0.35 | Aug 19, 2026 |
| Schwab Andrew J.Insider | Sell | $15 | 46at $0.32 | Aug 20, 2026 |
| 5AM Partners VII, LLCInsider | Sell | $15 | 46at $0.32 | Aug 20, 2026 |
| 5AM Partners VII, LLCInsider | Sell | $695 | 1,830at $0.38 | Aug 18, 2026 |
| 5AM Partners VII, LLCInsider | Sell | $96K | 253,080at $0.38 | Aug 18, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable SKYE activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.